Lonza To Invest in Mid-Scale Biomfg and Cell-Therapy Capacity

Lonza is investing in mid-scale mammalian cell biomanufacturing capacity and new cell-therapy suites at its site in Portsmouth, New Hampshire.  

Lonza plans to install multiple 6,000-liter bioreactors at the site with building expected to start in late 2018. Lonza is implementing full-suite process analytic technology (PAT) and advanced multi-variate analysis at the facility. The hybrid facility, which also incorporates single-use technologies, will be installed in an existing building.

In addition, Lonza is installing multiple cell-therapy suites at the Portsmouth site. In February 2018, the company established centers of excellence in cell and gene therapy across its network and placed Portsmouth as a clinical and commercial manufacturing center for cell and gene therapies. The suites will provide Phase I through to commercial manufacturing and are expected to be fully operational by late 2018.

Source: Lonza

Leave a Reply

Your email address will not be published. Required fields are marked *